Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree

by Carroll, N.V, Holdford, D.A, Ijioma, S.C, Pontinha, V.M
Published 2021

Optima TB: A tool to help optimally allocate tuberculosis spending

by Abeysuriya, R., Abou Jaoude, G.J, Abubakar, I., Benedikt, C., Cheikh, N., Fraser-Hurt, N., Gorgens, M., Goscé, L., Haghparast-Bidgoli, H., Hurevich, H., Hussain, A., Jarvis, S., Kedziora, D.J, Kelly, S.L, Kerr, C.C, Klimuk, D., Martin-Hughes, R., Palmer, T., Panovska-Griffiths, J., Roberts, A., Skordis, J., Skrahina, A., Stuart, R.M, Wilson, D.J, Wilson, D.P, Zhao, F.
Published 2021

Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT...

by Au, T., Biskupiak, J., Kharat, A.A, Nelson, R.
Published 2021

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer

by Hays, E., Le, V., Narsipur, N., Rosario, K., Tran, D.K, Wilson, L., Zhong, L.
Published 2021